(Q37913976)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826075%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

review article

1 reference

title

The pharmacogenetics of antiplatelet agents: towards personalized therapy? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826075%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826075%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Tariq Ahmad

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826075%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Richard C Becker

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826075%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

English

0 references

publication date

9 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826075%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Cardiology

9 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826075%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826075%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826075%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

560-571

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21826075%20AND%20SRC:MED&resulttype=core&format=json

ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association

9 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Variability in responsiveness to oral antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Intensifying platelet inhibition--navigating between Scylla and Charybdis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Cyclooxygenase-1 haplotype modulates platelet response to aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Aspirin and clopidogrel resistance: an emerging clinical entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Aspirin resistance: definition, mechanisms and clinical read-outs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Profile and prevalence of aspirin resistance in patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Pharmacogenetics of aspirin resistance: a comprehensive systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Pharmacogenomics of platelet responsiveness to aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

A combined genome-wide linkage and association approach to find susceptibility loci for platelet function phenotypes in European American and African American families with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Genetic variation in cyclooxygenase 1: effects on response to aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

The genetics of antiplatelet drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Aspirin resistance and a single gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Ticlopidine and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Genotyping: one piece of the puzzle to personalize antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Clinical pharmacogenetics and potential application in personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Effect of clopidogrel added to aspirin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

The case for routine genotyping in dual-antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Antiplatelet therapy: Personalized medicine for clopidogrel resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Pati

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Ca

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Associ

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Pharmacogenetics in cardiovascular antithrombotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Impact of P-glycoprotein on clopidogrel absorption

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Paraoxonase-1 is a major determinant of clopidogrel efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Risks of presymptomatic direct-to-consumer genetic testing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Another step on the road to tailored antiplatelet therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Unraveling myths of platelet function and genetic testing the road to making tailored antiplatelet therapy a reality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.111

Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21826075